Drug firm Lupin on Thursday said it has received approval from the U.S. health regulator to market a generic medication to treat diabetes.
The company has received approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application for Dapagliflozin and Saxagliptin tablets, the Mumbai-based drug maker said in a regulatory filing.
The company's product is a generic equivalent of AstraZeneca AB's Qtern tablets, it added.
This generic product will be manufactured at its Pithampur facility, the company said.
Dapagliflozin and Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
As per IQVIA data, Dapagliflozin and Saxagliptin tablets had estimated annual sales of $5 million in the U.S. market.
RECOMMENDED FOR YOU
Indian Tablet PC Market Grows 20% In Q2 FY25; Apple Leads With 30% Share: Cybermedia
Aug 16, 2025
Sun Pharma, Lupin, Dr. Reddy's Recall Products In US market
Jul 27, 2025
Dr Reddy's Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit
Jul 18, 2025
AstraZeneca Pharma Gets CDSCO Nod For Import, Sale Of Bladder Cancer Drug
Jul 14, 2025
POPULAR